Skip to Content
Merck
  • Defining immunological impact and therapeutic benefit of mild heating in a murine model of arthritis.

Defining immunological impact and therapeutic benefit of mild heating in a murine model of arthritis.

PloS one (2015-03-21)
Chen-Ting Lee, Kathleen M Kokolus, Nicholas D Leigh, Maegan Capitano, Bonnie L Hylander, Elizabeth A Repasky
ABSTRACT

Traditional treatments, including a variety of thermal therapies have been known since ancient times to provide relief from rheumatoid arthritis (RA) symptoms. However, a general absence of information on how heating affects molecular or immunological targets relevant to RA has limited heat treatment (HT) to the category of treatments known as "alternative therapies". In this study, we evaluated the effectiveness of mild HT in a collagen-induced arthritis (CIA) model which has been used in many previous studies to evaluate newer pharmacological approaches for the treatment of RA, and tested whether inflammatory immune activity was altered. We also compared the effect of HT to methotrexate, a well characterized pharmacological treatment for RA. CIA mice were treated with either a single HT for several hours or daily 30 minute HT. Disease progression and macrophage infiltration were evaluated. We found that both HT regimens significantly reduced arthritis disease severity and macrophage infiltration into inflamed joints. Surprisingly, HT was as efficient as methotrexate in controlling disease progression. At the molecular level, HT suppressed TNF-α while increasing production of IL-10. We also observed an induction of HSP70 and a reduction in both NF-κB and HIF-1α in inflamed tissues. Additionally, using activated macrophages in vitro, we found that HT reduced production of pro-inflammatory cytokines, an effect which is correlated to induction of HSF-1 and HSP70 and inhibition of NF-κB and STAT activation. Our findings demonstrate a significant therapeutic benefit of HT in controlling arthritis progression in a clinically relevant mouse model, with an efficacy similar to methotrexate. Mechanistically, HT targets highly relevant anti-inflammatory pathways which strongly support its increased study for use in clinical trials for RA.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Ethylenediaminetetraacetic acid, ACS reagent, 99.4-100.6%, powder
Sigma-Aldrich
Ethylenediaminetetraacetic acid, purified grade, ≥98.5%, powder
Sigma-Aldrich
Ethylenediaminetetraacetic acid, anhydrous, BioUltra, ≥99% (titration)
Sigma-Aldrich
Ethylenediaminetetraacetic acid, anhydrous, crystalline, BioReagent, suitable for cell culture
Sigma-Aldrich
Ethylenediaminetetraacetic acid disodium salt solution, BioUltra, for molecular biology, pH 8.0, ~0.5 M in H2O
Sigma-Aldrich
Potassium hydroxide, tested according to Ph. Eur.
Sigma-Aldrich
Ethylenediaminetetraacetic acid, ≥98.0% (KT)
Sigma-Aldrich
Ethylenediaminetetraacetic acid, BioUltra, ≥99.0% (KT)
Sigma-Aldrich
Sodium dodecyl sulfate solution, BioUltra, for molecular biology, 20% in H2O
Sigma-Aldrich
Sodium dodecyl sulfate solution, BioUltra, for molecular biology, 10% in H2O
Sigma-Aldrich
Ethylenediaminetetraacetic acid, 99.995% trace metals basis
Sigma-Aldrich
Ethylenediaminetetraacetic acid solution, 0.02% in DPBS (0.5 mM), sterile-filtered, BioReagent, suitable for cell culture
Sigma-Aldrich
Potassium hydroxide, free-flowing, Redi-Dri, ACS reagent, ≥85%, pellets
Sodium laurilsulfate, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Potassium hydroxide, anhydrous, ≥99.95% trace metals basis
Sigma-Aldrich
Potassium hydroxide, puriss., meets analytical specification of Ph. Eur., BP, 85-100.5%, pellets
Sigma-Aldrich
Potassium hydroxide, technical, ≥85%, powder
Sigma-Aldrich
Potassium hydroxide, BioXtra, ≥85% KOH basis
Methotrexate for peak identification, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Ethylenediaminetetraacetic acid, Vetec, reagent grade, 98%
Methotrexate, European Pharmacopoeia (EP) Reference Standard
SAFC
Methotrexate
Supelco
Methotrexate, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Potassium hydroxide, AR, flakes, ≥85%
Sigma-Aldrich
Potassium hydroxide, LR, flakes, ≥85%
Sigma-Aldrich
Ethylenediaminetetraacetic acid solution, 0.02 N
Sigma-Aldrich
Potassium hydroxide, AR, pellets, ≥85%
Sigma-Aldrich
Potassium hydroxide, LR, pellets, ≥85%
Sigma-Aldrich
Potassium hydroxide, puriss. p.a., ≥86% (T), pellets
Sigma-Aldrich
Potassium hydroxide, reagent grade, 90%, flakes